Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers.
about
Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.Practical considerations for the clinical use of buprenorphine.Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals.A review of human drug self-administration procedures.The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers.Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.Prevention of HIV infection among injection drug users in resource-limited settings.Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine.Choice of sevoflurane and its subjective and psychomotor effects in light and moderate drinkers.Opioid maintenance: a comparative review of pharmacological strategies.Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.Controversies in translational research: drug self-administration.The role of human drug self-administration procedures in the development of medications.The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers.Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey.Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study.Opioid substitution therapy for dependent health care practitioners: approach with cautionUse and misuse of opioid replacement therapies: a Queensland study.Clinical models of decision making in addiction.
P2860
Q33751060-D58B79A2-D4CE-427C-A993-A20792EEAB73Q33774853-4FC92D81-F9C2-4B90-A6C6-34183F266017Q33837582-D627C5FB-6501-429D-B2F5-669ACA2D86B9Q33841805-7B141832-6B14-47D4-B6AE-F7727EB617F9Q33889324-20414E4F-4009-4E2C-8A73-58583BA89129Q34081656-61B4D40E-33BB-4113-9E09-62BADB19F7C0Q34138291-B72644B3-A537-4399-99AF-A1248CA3BD05Q35009760-86A103BD-9B52-421E-BB4E-89A01E9E3DDBQ35043964-27C50EE5-C31F-45AB-B01D-1E9AE904E914Q35160035-A317FB37-187A-40DD-B950-8EA49DC225F7Q36253355-F29FF2E6-45BB-45F9-B43C-06BA20F301C2Q36528682-D65CF8A8-70B9-432E-8409-49AE0CBD7DC7Q36681297-12D79EBE-45E2-49FE-8519-40C31BA864F3Q37045335-1F89AF2A-C536-42D3-8E6E-48AF0612B823Q37087986-5FABC5AF-3907-449B-BF79-96501E8C3423Q37147515-9A14EAC0-6998-4C1F-B141-F6BEC12640D7Q37180966-27C412F8-3066-43C5-95A8-7F5CDAC6FBEDQ37208977-4B87A87C-825A-4C5B-A221-DCEFB7030F8CQ37282456-D05AFB19-68E0-45B3-86F1-C5A03BC88D30Q37346293-FFAA7682-793D-4E0F-B632-01C985D6E4C3Q37407584-3E53B38B-D3BA-4CAA-A0DD-C27FA01B6745Q37587221-191586C2-B5E6-4404-9543-61372C0F1AAFQ38374886-65B17F5B-29AE-4986-9AB2-DC97989B8638Q41466780-553326B5-C26E-4E24-A920-E417E1531E95Q42336473-EB2960F3-01EA-49F4-AB30-5FC2CD96A29AQ44332368-ACD082E2-931F-4E2C-AD9B-BE37B9DA3502Q45066213-EDDD4818-A121-45B8-82BC-483D2B11F4B0
P2860
Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Self-administration of intrave ...... tly detoxified heroin abusers.
@ast
Self-administration of intrave ...... tly detoxified heroin abusers.
@en
type
label
Self-administration of intrave ...... tly detoxified heroin abusers.
@ast
Self-administration of intrave ...... tly detoxified heroin abusers.
@en
prefLabel
Self-administration of intrave ...... tly detoxified heroin abusers.
@ast
Self-administration of intrave ...... tly detoxified heroin abusers.
@en
P2860
P356
P1476
Self-administration of intrave ...... tly detoxified heroin abusers.
@en
P2093
Eric D Collins
Sandra D Comer
P2860
P304
P356
10.1124/JPET.102.038141
P407
P577
2002-11-01T00:00:00Z